Lv3
348 积分 2025-05-09 加入
Global trends and regional variations in PCa burden: A focus on China's rapid growth
9天前
已完结
Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases
10天前
已完结
Quad‐class exposed/refractory myeloma is associated with short survival
13天前
已完结
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
14天前
已完结
Colorectal cancer burden, trends, and risk factors in China: rising incidence and disparities in the last 3 decades
20天前
已完结
Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline
20天前
已完结
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
20天前
已完结
Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164
20天前
已完结
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study
20天前
已完结
Calgb/Swog 80405: Phase III Trial of Irinotecan/5-Fu/Leucovorin (Folfiri) or Oxaliplatin/5-Fu/Leucovorin (Mfolfox6) with Bevacizumab (Bv) or Cetuximab (Cet) for Patients (Pts) with Expanded Ras Analyses Untreated Metastatic Adenocarcinoma of the Colon Or Rectum (Mcrc)
21天前
已完结
Hepatocyte nuclear factor 4α multiple isoforms, their functions, and their interactomes
24天前
已采纳
Rumor propagation on hypergraphs
24天前
已采纳
Dynamic Evolution of Polar Regions in KTa0.56Nb0.44O3 near the Para-Ferroelectric Phase Transition
24天前
已采纳
Evolve and Revoke: A Secure and Efficient Conditional Proxy Re-Encryption Scheme with Ciphertext Evolution
24天前
已采纳
Comprehensive review on the pathophysiology, clinical variants and management of pemphigus (Review)
24天前
已采纳
皖公网安备34019202002308
